Pascal is the CEO of Genoskin, a life science company he founded in 2011, based in Salem MA and Toulouse, France. Genoskin is a leader and pioneer of ex vivo clinical testing thanks to its unique platform of standardized ex vivo human skin models that provides reliable human data. Pascal did his Ph.D. at the University of Toulouse, France under Prof. Alain Hovnanian at the National Institute of Health and Medical Research. He successfully developed and characterized a mouse model for Netherton syndrome, a severe genodermatosis with atopic symptoms. Pascal then did a postdoc in the laboratory of Dr. Mickael Karin at the University of San Diego California where he studied the role of the alpha subunit of the IKK complex in keratinocyte cell cycle arrest and commitment to epidermal terminal differentiation. In 2009, Pascal developed innovative human skin models at the French National Center for Scientific Research and the University of Toulouse. He invented a unique gel-like matrix to keep human skin biopsies alive. This innovative technology led Pascal to launch Genoskin. In 2018, Pascal moved to the US to establish Genoskin Inc. and further develop its North American capabilities. Pascal has 20 years of experience in the development and characterization of pathological skin models and his research has been published in major journals, such as Nature Genetics, PNAS, EMBO and the Journal of Investigative Dermatology. Pascal is the inventor of 4 patent families owned by Genoskin. He also received the LeoPharma Charles Grupper Award (2005), the Award for Medicine from the Toulouse Academy of Science (2007) as well as the Young Entrepreneur Award of Economy from “La Tribune” (2014).